NEW YORK, Aug. 27, 2015 /PRNewswire/ -- Biological drugs
are typically derived from living cells and are used in the
prevention and treatment of various diseases such as cancer, blood
disorders, auto-immune diseases and other medical conditions.
Biological drugs have more complex structures compared to that of
conventional drugs. These are highly sensitive and more difficult
to characterize and develop. A biological drug typically has around
250 in-process tests during manufacturing compared to around 50
tests for a conventional drug.
The increasing prevalence of chronic diseases and growing geriatric
population are the major drivers of the global biological drugs
market. In addition, various government associations are also
supporting the growth of the biological drugs market. Furthermore,
advancements in biomedical science hold immense potential for the
growth of the biological drugs market. However, high costs of
biological drugs and patent expiry of blockbuster drugs impede the
growth of the biological drugs market. Moreover, risks of adverse
effects associated with biologic injectable drugs are also
inhibiting the growth of the biological drugs market.
In terms of geography, North
America dominates the global biological drugs market. This
is due to increasing use of biological drugs for the treatment of
diseases such as cancer, diabetes, and other chronic diseases. In
addition, various government associations are promoting the usage
of biological drugs in North
America. For instance, in 2012, the American College of
Rheumatology – an organization that advances rheumatology through
education and research – recommended biologic agents and
disease-modifying antirheumatic drugs for the treatment of
rheumatoid arthritis.
In Europe, the biological drugs
market is growing due to increasing aging population in the region.
According to a UN report, elderly people accounted for 23.2% of the
total population in Germany in
2000, and the number is expected to reach 33.2% by 2025. Aging can
lead to certain disorders such as age-related macular degeneration
and glaucoma, which require biological drugs for their effective
treatment.
Low manufacturing costs in Asia
attract biopharmaceutical companies to invest in the region. For
instance, Lonza – a Switzerland-based biotechnology company –
invested around US$ 350 Mn in
Singapore and India, in order to encourage biological
activities.
This report provides in-depth analysis and estimation of the
biological drugs market for the period 2014–2020, considering 2014
as the base year for the calculation. In addition, data pertaining
to current market dynamics, including market drivers, restraints,
trends, and recent developments, has been provided in the report.
The global biological drugs market is categorized based on
therapeutic protein, monoclonal antibodies (mAb), and vaccines.
Based on therapeutic protein, the market segments include Enbrel,
Lantus, Neulasta, Avonex, NovoLog, Rebif, Humalog, Aranesp, Epogen,
Levemir, Victoza, Betaseron, Neupogen, and Eylea. Based on mAb, the
report comprises Humira, Remicade, Rituxan, Avastin, Herceptin, and
Lucentis. The vaccine segment is further sub-segmented into Prevnar
13, Gardasil, Fluzone, Varivax, and Cervarix. On the basis of
geography, the report identifies and analyzes the market size and
predictions for North America,
Europe, Asia, and Rest of the World (RoW).
Some of the major players in the biological drugs market are Pfizer
Inc., Abbott Laboratories, Novartis AG, Eli Lilly and Company,
GlaxoSmithKline plc., Bristol-Myers Squibb Company, Merck &
Co., Inc., Amgen Inc., Baxter International Inc., and Biogen Idec.
These key market players have been profiled on the basis of
attributes such as company overview, recent developments, growth
strategies, sustainability, and financial overview.
Read the full report:
http://www.reportlinker.com/p03175789-summary/view-report.html
About Reportlinker
ReportLinker is an award-winning market research solution that
finds, filters and organizes the latest industry data so you get
all the market research you need - instantly, in one place.
http://www.reportlinker.com
__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/global-market-study-on-biological-drugs-north-america-to-witness-highest-growth-by-2020-300134440.html
SOURCE Reportlinker